GSK has secured its first-ever lung cancer drug approval after the US Food and Drug Administration cleared Jideytro, delivering a rapid return on the company’s major acquisition.
The FDA approved the drug ahead of its September 18 target date, marking a swift payoff from GSK’s $10.6 billion acquisition of Nuvalent, the cancer-focused biotech behind the treatment.
The approval represents a significant milestone for GSK, which has been expanding its oncology portfolio aggressively through dealmaking in recent years.
Jideytro’s accelerated clearance underscores the FDA’s willingness to move quickly on treatments targeting cancers with limited existing options for patients.
GSK trades on the London Stock Exchange and on the New York Stock Exchange under the ticker GSK, and investors are likely to view the approval as validation of the Nuvalent deal’s strategic rationale.
In other industry news, US biotech Axiom Biosciences is charting an unconventional path to the public markets by choosing to list first in Hong Kong before pursuing a co-listing on the Nasdaq exchange.
The move is notable given that most US-based biotechs seeking public capital have traditionally looked to domestic exchanges first, making Axiom’s approach a genuine outlier in the sector.
The decision comes amid a resurgent biotech IPO market, with investor appetite for life sciences companies recovering meaningfully after a prolonged period of subdued listings activity.
Separately, the US House of Representatives passed legislation directing the FDA to update its rules around animal testing requirements for drug development, a move that could reshape how pharmaceutical companies bring new treatments to clinical trials.
The shift in regulatory expectations around animal testing reflects broader scientific advances in areas such as organoids, computer modelling and lab-grown tissue that offer alternatives to traditional preclinical methods.
The stories were highlighted in a recent episode of the Fierce Pharma podcast, which also included a newsroom update announcing the arrival of a new Fierce Biotech staff writer and a reflection on the enduring importance of human judgment, curiosity and original reporting in an era of rapidly advancing artificial intelligence tools.